PARP1: A potential biomarker for gastric cancer

被引:17
|
作者
Afzal, Hifza [1 ]
Yousaf, Shahzad [1 ]
Rahman, Faisal [2 ]
Ahmed, Malik Waqar [1 ]
Akram, Zertashia [1 ]
Kayani, Mahmood Akhtar [1 ]
Mahjabeen, Ishrat [1 ]
机构
[1] COMSATS Univ, Dept Biosci, Pk Rd, Islamabad, Pakistan
[2] Fed Govt Educ Inst, Rawalpindi, Pakistan
关键词
BER pathway; APEX1; PARP1; Gastric cancer; H pylori; Smoking; OXIDATIVE STRESS; INCREASED RISK; DNA-DAMAGE; EXPRESSION; REPAIR; GENES; HEAD; PROLIFERATION; ASSOCIATION; SMOKING;
D O I
10.1016/j.prp.2019.152472
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Gastric cancer (GC) is the third leading cause of cancer mortality worldwide, with an overall 5-y survival rate of 25%. The majority of GCs are caused by infectious agents, including the bacterium Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV). Furthermore, inappropriate repair of DNA damage can also result in genomic instability, which has shown to be a key factor in carcinogenesis of different regions including gastric region. Present study was designed to explore the association between base excision repair pathway genes, PARP1 and APEX) and gastric pathology and H. pylori infection. Two hundred gastric cancer tissue samples (114 H. pylori positive and 86 H. pylori negative) and adjacent uninvolved area taken as controls was used for expression analysis of BER pathway genes at mRNA level and protein levels using quantitative PCR (qPCR) and immunohistochemistry (IHC) respectively. Oxidative stress and DNA damage was also determined by measuring the level of antioxidant enzymes and comet assay respectively. Significant upregulation in PARP1 (p < 0.001) and APEX1 (p < 0.02) was observed in GC tissue samples compared to controls and this upregulation was more pronounced in H. pylori positive cases (HPGC) (PARP1, p < 0.02: APEX1, p < 0.04) than H. pylori negative cases (HNGC). Upregulation of BER pathway genes in HPGC was found correlated with smoking status (p < 0.0001), T stage (p < 0.01) and lymph node metastasis (p < 0.03). Moreover, immunohistochemical staining of BER pathway genes was found correlated with a number of clinicopathological characteristics such as tumor type (p < 0.03), tumor size (p < 0.01) and lymph node metastasis (p < 0.01). Expression levels of APEX) and PARP1 gene also correlated with increased oxidative burden (p < 0.0001) and DNA damage (p < 0.001) in GC patients. Survival analysis showed that upregulation of PARP1 gene was associated with poor overall survival outcome of gastric cancer patients (HR = 2.04 (95% CI = 1.10-3.76; p < 0.02). Univariate and multivariate cox regression analysis showed the upregulated PARP1 gene (HR = 5.03; 95%CI (2.22-11.35); p = 0.0001), positive smoking status (HR = 3.58; 95%CI (1.67-7.65); p = 0.001), positive status for H pylori infection (HR = 4.38; 95%CI (1.82-10.56); p = 0.001) and advance N-stage (HR = 5.29; 95%CI (2.28-12.24); p = 0.0001) were independent prognostic factors for gastric cancer and may serve as a valuable biomarker for the diagnosis and progression of GC and can be helpful in developing individualized treatment strategies for treating GC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] PARP1 Polymorphisms Increase the Risk of Gastric Cancer in a Chinese Population
    Wenting He
    Tao Liu
    Yong Shan
    Kexiang Zhu
    Yumin Li
    Molecular Diagnosis & Therapy, 2012, 16 : 35 - 42
  • [2] PARP1 Polymorphisms Increase the Risk of Gastric Cancer in a Chinese Population
    He, Wenting
    Liu, Tao
    Shan, Yong
    Zhu, Kexiang
    Li, Yumin
    MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (01) : 35 - 42
  • [3] α-Aminophosphonates as Potential PARP1 Inhibitors
    Schweiker, Stephanie S.
    Tauber, Amanda L.
    Kam, Caleb M.
    Eyckens, Daniel J.
    Henderson, Luke C.
    Levonis, Stephan M.
    CHEMISTRYSELECT, 2020, 5 (14): : 4205 - 4209
  • [4] Transcriptional Roles of PARP1 in Cancer
    Schiewer, Matthew J.
    Knudsen, Karen E.
    MOLECULAR CANCER RESEARCH, 2014, 12 (08) : 1069 - 1080
  • [5] The Nucleolus and PARP1 in Cancer Biology
    Engbrecht, Marina
    Mangerich, Aswin
    CANCERS, 2020, 12 (07) : 1 - 21
  • [6] Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
    Peng, Xiaopeng
    Pan, Wanyi
    Jiang, Feng
    Chen, Weiming
    Qi, Zetao
    Peng, Weijie
    Chen, Jianjun
    PHARMACOLOGICAL RESEARCH, 2022, 186
  • [7] NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients
    Mangia, Anita
    Scarpi, Emanuela
    Partipilo, Giulia
    Schirosi, Laura
    Opinto, Giuseppina
    Giotta, Francesco
    Simone, Giovanni
    ONCOTARGET, 2017, 8 (39) : 65730 - 65742
  • [8] PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
    Wang, Luyao
    Liang, Chao
    Li, Fangfei
    Guan, Daogang
    Wu, Xiaoqiu
    Fu, Xuekun
    Lu, Aiping
    Zhang, Ge
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (10)
  • [9] TOPBP1 regulates resistance of gastric cancer to oxaliplatin by promoting transcription of PARP1
    Fang, Zejun
    Gong, Chaoju
    Ye, Zhuoni
    Wang, Wei
    Zhu, Minjing
    Hu, Yanyan
    Liu, Zhiguo
    Zhou, Weihua
    Li, Hongzhang
    DNA REPAIR, 2022, 111
  • [10] PARP1 in triple-negative breast cancer: Expression and therapeutic potential
    Cotter, M. B.
    Pierce, A.
    McGowan, P. M.
    Madden, S. F.
    Flanagan, L.
    Quinn, C.
    Evoy, D.
    Crown, J.
    McDermott, E.
    Duffy, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)